



---

# Psychedelics promote plasticity by directly binding to BDNF receptor TrkB

---

In the format provided by the authors and unedited

**Supplementary Table 3.** Simulated systems. The table lists the variants of TM TrkB dimers embedded in POPC-CHOL lipid membranes, mole percentage of cholesterol ( $\rho_{\text{CHOL}}$ ), the number of POPC ( $N_{\text{POPC}}$ ) and cholesterol ( $N_{\text{CHOL}}$ ) molecules in a membrane, the number of independent simulation repeats ( $N_{\text{sim}}$ ), and the simulation length per repeat ( $t_{\text{sim}}$ ). “WT”, “Y433F.homo”, and “V437A.homo” refer in respective order to the wild-type and homozygous Y433F and V437A variants of a TrkB TM dimer (residues 427-459). LSD, LSD<sup>+</sup>: psychoactive (+)-LSD (in a 5R,8R configuration) in a neutral and protonated form. PSI, PSI<sup>+</sup>: psilocin in a neutral and protonated form. Lisuride, Lisuride<sup>+</sup>: lisuride in a neutral and protonated form. CAR: cabergoline in a neutral form (pKa = 6.22). DHE: dihydroergotamine in a neutral form (pKa = 6.75).

System name	Protein variant	Drug type	$\rho_{\text{CHOL}}$ (mol%)	$N_{\text{POPC}}$	$N_{\text{CHOL}}$	$N_{\text{sim}}$	$t_{\text{sim}}$ ( $\mu\text{s}$ )
System 1 <sup>#</sup>	WT	LSD	20	112	28	100	1
System 2 <sup>∇</sup>	WT	LSD	20	112	28	20	2
System 3 <sup>∇</sup>	WT	LSD <sup>+</sup>	20	112	28	20	2
System 4 <sup>∇</sup>	WT	PSI	20	112	28	20	2
System 5 <sup>∇</sup>	WT	PSI <sup>+</sup>	20	112	28	20	2
System 6 <sup>∇</sup>	WT	Lisuride	20	112	28	20	2
System 7 <sup>∇</sup>	WT	Lisuride <sup>+</sup>	20	112	28	20	2
System 8 <sup>∇</sup>	WT	CAR	20	112	28	20	2
System 9 <sup>∇</sup>	WT	DHE	20	112	28	20	2
System 10 <sup>∇</sup>	Y433F	LSD	20	112	28	20	2
System 11 <sup>∇</sup>	V437A	LSD	20	112	28	20	2
System 12 <sup>∇</sup>	Y433F	LSD <sup>+</sup>	20	112	28	20	2
System 13 <sup>∇</sup>	V437A	LSD <sup>+</sup>	20	112	28	20	2
System 14 <sup>∇</sup>	Y433F	PSI <sup>+</sup>	20	112	28	20	2
System 15 <sup>∇</sup>	V437A	PSI <sup>+</sup>	20	112	28	20	2
System 16 <sup>†</sup>	WT	LSD	20	112	28	1	0.06
System 17 <sup>†</sup>	Y433F	LSD	20	112	28	1	0.06
System 18 <sup>†</sup>	V437A	LSD	20	112	28	1	0.06
System 19 <sup>†</sup>	WT	LSD <sup>+</sup>	20	112	28	1	0.06
System 20 <sup>†</sup>	Y433F	LSD <sup>+</sup>	20	112	28	1	0.06
System 21 <sup>†</sup>	V437A	LSD <sup>+</sup>	20	112	28	1	0.06
System 22 <sup>†</sup>	WT	PSI	20	112	28	1	0.06
System 23 <sup>†</sup>	WT	PSI <sup>+</sup>	20	112	28	1	0.06
System 24 <sup>†</sup>	Y433F	PSI <sup>+</sup>	20	112	28	1	0.06
System 25 <sup>†</sup>	V437A	PSI <sup>+</sup>	20	112	28	1	0.06
System 26 <sup>†</sup>	WT	Lisuride	20	112	28	1	0.06
System 27 <sup>†</sup>	WT	Lisuride <sup>+</sup>	20	112	28	1	0.06
System 28 <sup>†</sup>	WT	CAR	20	112	28	1	0.16
System 29 <sup>†</sup>	WT	DHE	20	112	28	1	0.06
System 30 <sup>§</sup>	WT	-	40	90	60	10	1
System 31 <sup>§</sup>	WT	LSD	40	90	60	10	1
System 32 <sup>§</sup>	WT	LSD <sup>+</sup>	40	90	60	10	1
System 33 <sup>§</sup>	WT	PSI <sup>+</sup>	40	90	60	10	1
System 34 <sup>§</sup>	WT	Lisuride <sup>+</sup>	40	90	60	10	1

# Simulations to explore LSD binding site and mode.

∇ Simulations to optimize the binding modes of each drug in the wild type and mutated TM TrkB dimers.

† FEP/HREX (free energy) simulations to estimate the drug binding affinities.

§ Simulations to explore the effect of cholesterol and the drugs on the conformation of the protein.